An anti-emap II monoclonal antibody as a first-in-class treatment for group III pulmonary hypertension patients with chronic obstructive pulmonary disease - 1 abstract 2 3 the key goal of this…
Active Grant Awarded
- Award ID
- R44HL186831
- Recipient
-
Allinaire Therapeutics, LLC UEI K5GFMW6QF1P7
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,498,892
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 10% complete
- Place of performance
- Cleveland, OH 44106, USA
Award details come from USAspending.gov.
About this award
The National Institutes of Health's National Heart, Lung, and Blood Institute, within the Department of Health and Human Services, awarded Allinaire Therapeutics, LLC a grant of $1.498892 million on Sep 9, 2026, under Assistance Listing 93.837, Cardiovascular Diseases Research. The award is a direct-to-Phase II Small Business Innovation Research (SBIR) grant, and the full amount is obligated. Allinaire will conduct IND-enabling studies of a neutralizing monoclonal antibody against endothelial monocyte-activating polypeptide II (EMAP II), a first-in-class candidate for Group 3 pulmonary hypertension linked to chronic obstructive pulmonary disease (COPD-PH), a population with no approved medicines. The initial indication targets COPD-PH rather than COPD or pulmonary arterial hypertension, based on target validation in both diseases, the unmet medical need, and interest from potential pharmaceutical licensing partners. The project period runs from the award date through Aug 31, 2028, with performance in Cleveland, OH 44106, USA. The SBIR program stimulates technological innovation by using small businesses to meet federal research and development needs. Under its terms, SBIR awards go only to U.S. small business concerns with no more than 500 employees including affiliates, and the principal investigator must be primarily employed by the small business.
Description
An anti-emap II monoclonal antibody as a first-in-class treatment for group III pulmonary hypertension patients with chronic obstructive pulmonary disease - 1 abstract 2 3 the key goal of this direct-to-phase II sbir proposal is for ALLINAIRE therapeutics (ALLINAIRE) to 4 conduct IND-enabling studies with a neutralizing monoclonal antibody (MAB) against endothelial 5 monocyte-activating polypeptide II (emap II), a first-in-class, disease-modifying treatment for 6 patients with group 3 pulmonary hypertension linked to chronic obstructive pulmonary disease- 7 linked PH (COPD-PH), a patient population with no approved medicines. COPD is a progressive, 8 deadly lung disease mainly due to cigarette smoke (CS). PH, a devastating disease categorized into 5 9 groups, is a common feature of COPD, and linked to worsening of symptoms and outcomes. Unlike the 10 rare group 1 PH (PAH) there are no approved treatments for group 3 COPD-PH, which is much more 11 common and more lethal than PAH, highlighting the massive unmet clinical need. Our studies have 12 provided strong evidence for a key role of emap II in both COPD and PAH, including: I) lung emap II 13 levels are elevated in lungs of COPD and group 1 and 3 PH; II) lung-specific over-expression of emap 14 II in mice produces COPD- and PH-like features; III) a tool anti-rodent emap II neutralizing MAB is 15 effective in various models of COPD and PAH. Therefore, IT is hypothesized that targeting emap II, a 16 driver of COPD and PH pathogenesis, using an anti-emap II MAB will be safe and effective in COPD- 17 PH patients by inhibition of lung injury and damage, pulmonary inflammation, pulmonary vascular 18 remodeling, and RV dysfunction. ALLINAIRE has focused on COPD-PH, rather than COPD or PAH, as the 19 initial indication because of the combination of strong target validation in both diseases, huge unmet 20 medical need (compared to PAH), increased interest in COPD-PH and more potential pharmaceutical 21 licensing partners (compared to COPD alone). After affinity maturation of the initial lead humanized and 22 human anti-emap II mabs, ALLINAIRE identified a clinical development candidate (CDC) MAB, alli-925, 23 to progress. The main objectives of this phase IIB sbir proposal are: aim 1. Demonstrate the efficacy 24 of the CDC anti-emap II MAB, alli-925, in a mouse model of COPD-PH. The dose-response effects 25 of subcutaneous administration of alli-925, will be examined in a mouse model of COPD-PH, involving 26 exposure to cigarette smoke+hypoxia, measuring RV hypertrophy, and several hemodynamic, pulmonary 27 function, lung inflammation, lung damage and vascular remodeling endpoints. Aim 2. Conduct IND- 28 enabling studies with alli-925. The following standard safety and toxicokinetic studies, including 29 measurement of anti-drug antibodies, will be conducted: 29-day dose-range finding study after S.C. 30 administration, followed by a 13-week toxicity study, both in the cynomolgus monkey. Completion of 31 these studies are critical to an IND submission and clinical trials with alli-925 as a disease-modifying 32 therapy to COPD-PH patients, for which there are currently no approved drugs.
Quick answers
Who received award R44HL186831?
R44HL186831 was awarded to Allinaire Therapeutics, LLC by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.
How much is award R44HL186831 worth?
$1,498,892 has been obligated on R44HL186831.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award